# CDMO.BOT / KETABALM

- **Event:** [Nebius.Build SF](https://cerebralvalley.ai/e/nebius-build-sf)
- **When:** Sun, Mar 15 at 9:00 AM – 10:00 PM (PDT)
- **Where:** Shack15, San Francisco, CA
- **Team:** [Lorenzo Carver](https://cerebralvalley.ai/u/TRIPBalm)
- **GitHub:** https://github.com/FludAI/cdmobot-backend
- **Demo video:** https://youtu.be/1_B-RzK1qUM
- **Gallery:** https://cerebralvalley.ai/e/nebius-build-sf/hackathon/gallery
- **Page:** https://cerebralvalley.ai/e/nebius-build-sf/hackathon/gallery/9

CDMO Bot is an autonomous robotic compounding system that turns idle pharmaceutical cleanroom capacity into a distributed manufacturing network for personalized therapeutics.

The system runs a continuous closed-loop: biometric sensors feed a Nebius LLM dosing agent that reasons about receptor pharmacology, an orchestrator dispatches tasks to a simulated Unitree G1 humanoid in Isaac Sim, and a validation layer verifies every cycle against the directive — all without human intervention. The dashboard is an observability window into the autonomous loop, not the control surface.

The primary consumers of inference are other agents and robots, not humans. Nebius Token Factory runs continuously as the reasoning backbone — deciding doses, planning robot skill sequences, and self-correcting when validation fails. Every cycle produces a timestamped audit event with inference cost attribution, creating a per-dose financial ledger. But if you want to get a drug, compounding/cdmo excited enough to take the leep - you have to give them a dashboard :) 

Market: The global CDMO market is ~$180B in 2026, growing at 7%+ CAGR to $340B+ by 2035. The U.S. compounding pharmacy market alone is $7.4B in 2026 growing to $12.8B by 2035. Small and mid-size CDMOs face chronic capacity volatility when venture-backed biotech clients cancel — our system monetizes that idle cleanroom capacity.

Economics: A single ~600 sq ft robotic node costs ~$870K/yr to operate and produces up to $7.5M in annual revenue at 50% utilization. At 5 nodes, platform revenue reaches ~$13M/yr. At 8–12× healthtech infrastructure multiples, that's a $100–$150M valuation — a 20–30× return on $5M deployment capital.

Two scenarios on the same G1 sim: caffeine transdermal balm (adenosine receptors) and ketamine therapeutic balm (NMDA/opioid/GABA/sigma). Patent pending — built on the Reverse-FDA Trial framework where real-world dosing events generate regulatory-grade evidence.

Stack: React 19 + Vite + Tailwind, FastAPI + Python, Isaac Sim + MuJoCo (dual sim), Nebius Token Factory Llama 3.1 70B (continuous inference), Nebius AI Cloud L40S.

---

Markdown version of https://cerebralvalley.ai/e/nebius-build-sf/hackathon/gallery/9. Site index for agents: https://cerebralvalley.ai/llms.txt · full text: https://cerebralvalley.ai/llms-full.txt